ViroGates Corporate Profile
ViroGates is an international biotech company headquartered in Copenhagen, Denmark. ViroGates develops and distributes prognostic products for healthcare management with a single goal in mind: To identify risk patients early and improve the lives of seriously infected people globally. The novel ViroGates method involves the measurement of a protein found in every individual known as soluble urokinase Plasminogen Activator Receptor (suPAR). suPAR has a unique value as prognostic biomarker: Independent of the respective condition, an elevated suPARnostic® level carries a negative prognostic value and can thus be a master alarm for patient risk status. In clinical practice suPARnostic®’s application should be in patient triaging in critical care as well as for monitoring of treatment efficacy and success. suPARnostic®’s prognostic value has been exemplified in various infectious conditions through a number of studies, these include sepsis, tuberculosis and HIV.
ViroGates’ first commercial product - suPARnostic® - is an ELISA-based test kit for the quantitative determination of suPAR in human EDTA plasma. suPARnostic® holds the CE/IVD mark and provides a simple, cost-effective and highly transportable clinical monitoring tool. ViroGates has launched suPARnostic® in certain European, African and Asian countries. Further products are being developed: A lateral flow rapid test - suPARnostic® Quick - is in final stages of development as well as line extensions to the current kit.
Press Releases
Latest Press Releases:
2011-08-22
ViroGates has been granted a new patent to measure the risk of developing life style related diseases using its suPARnostic® biomarker product
20110822 Press Release ViroGates: New patent grant
20110822 Pressemeddelelse ViroGates: Nyt patent udstedt
Media Queries
Please contact Jakob Knudsen, CEO (+45 2226 1355 or This e-mail address is being protected from spambots. You need JavaScript enabled to view it )
